Clay B. Siegall, Ph.D. has been appointed by Mirna Therapeutics to its Board of Directors. This firm is in the biotechnology sector. It is focused on developing and commercializing a number of microRNA (miRNA) therapeutics.
Presently Clay B. Siegall, Ph.D., is the co-founder as well as the President of the company called Seattle Genetics. He is working here as the Chief Executive Officer as well as the Chairman of the Board of Directors.
He has wide experience in the field of pharmaceuticals. He has won several awards. He has built a highly successful oncology firm. Hence the Mirna team is planning to make use of these attributes as this can help to advance the development of several therapeutic based on microRNA.
Clay B. Siegall finds this microRNA-based therapeutics as an exciting new field of research on cancer. This is why he feels that Mirna is quite well-placed with its strong lineup of product candidates. Thus he wants to team up with them to advance their programs for the patients who need such programs.
He is going to provide his unique leadership here. This would comprise of having a diverse pipeline that has distinct therapies. These are based on antibodies developed by the company. These will address different medical requirements of those who are suffering from cancer.
The first commercial product that was developed here was ADCETRIS® (brentuximaesid vedotin). It got approved in 2011. Besides, there would be many other products for this company.
Seattle Genetics is going to enter into various other strategic collaborations. These will be with a number of biotechnology as well as pharmaceutical companies in the field of oncology.
Clay B. Siegall is looking into several activities which are linked to raising capital for Seattle Genetics. He has been able to secure $675 million for his company.